cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Oncternal Therapeutics Inc
7 own
23 watching
Current Price
$0.3
$0.01
(1.83%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
17.65M
52-Week High
52-Week High
1.87
52-Week Low
52-Week Low
0.261
Average Volume
Average Volume
0.15M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization17.65M
icon52-Week High1.87
icon52-Week Low0.261
iconAverage Volume0.15M
iconDividend Yield--
iconP/E Ratio--
What does the Oncternal Therapeutics Inc do?
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Read More
How much money does Oncternal Therapeutics Inc make?
News & Events about Oncternal Therapeutics Inc.
Ticker Report
1month ago
Maxim Group downgraded shares of Oncternal Therapeutics (NASDAQ:ONCT Get Rating) from a buy rating to a hold rating in a research report released on Tuesday, The Fly reports. Other equities research analysts have also recently issued reports about the stock. HC Wainwright cut shares of ...
Globe Newswire
2 months ago
SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Oncternal ...
Zolmax
2 months ago
Oncternal Therapeutics (NASDAQ:ONCT Get Rating) had its price target reduced by equities researchers at Oppenheimer from $14.00 to $9.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has an outperform rating on the stock. Several other research ...
Benzinga
2 months ago
read more...
Globe Newswire
6 months ago
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 will be presented in an ...
Frequently Asked Questions
Frequently Asked Questions
What is Oncternal Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Oncternal Therapeutics Inc shares?
plus_minus_icon
How can I buy Oncternal Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Oncternal Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Oncternal Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Oncternal Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Oncternal Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Oncternal Therapeutics Inc?
plus_minus_icon
What percentage is Oncternal Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Oncternal Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.3
$0.01
(1.83%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
$0.28
$-0.01 (-2.89 %)
Angion Biomedica Corp
Angion Biomedica Corp
$0.95
$0.10 (11.75 %)
Humanigen Inc
Humanigen Inc
$0.15
$0.00 (1.70 %)
I-Mab
I-Mab
$3.11
$0.12 (4.01 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
$0.28
$-0.01 (-2.89 %)
Angion Biomedica Corp
Angion Biomedica Corp
$0.95
$0.10 (11.75 %)
Humanigen Inc
Humanigen Inc
$0.15
$0.00 (1.70 %)
I-Mab
I-Mab
$3.11
$0.12 (4.01 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00